HVO Stock Overview
Operates as a pharmaceutical service and contract research company in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.29 |
| 52 Week High | UK£0.32 |
| 52 Week Low | UK£0.17 |
| Beta | 0.97 |
| 11 Month Change | -0.86% |
| 3 Month Change | 6.45% |
| 1 Year Change | 60.33% |
| 33 Year Change | 13.33% |
| 5 Year Change | 334.59% |
| Change since IPO | 325.00% |
Recent News & Updates
Recent updates
hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price
Jan 26
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified
Jan 03At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?
Nov 30A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price
Jun 14A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)
Feb 01Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?
Dec 20Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?
Sep 13Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?
Jun 02Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Feb 15How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
Dec 23Calculating The Fair Value Of Open Orphan plc (LON:ORPH)
Nov 18Shareholder Returns
| HVO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -1.7% | 10.9% | -2.4% |
| 1Y | 60.3% | -25.7% | 7.6% |
Return vs Industry: HVO exceeded the UK Life Sciences industry which returned -25.7% over the past year.
Return vs Market: HVO exceeded the UK Market which returned 7.6% over the past year.
Price Volatility
| HVO volatility | |
|---|---|
| HVO Average Weekly Movement | 3.2% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HVO has not had significant price volatility in the past 3 months.
Volatility Over Time: HVO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations.
hVIVO plc Fundamentals Summary
| HVO fundamental statistics | |
|---|---|
| Market cap | UK£196.63m |
| Earnings (TTM) | UK£16.12m |
| Revenue (TTM) | UK£58.67m |
12.2x
P/E Ratio3.4x
P/S RatioIs HVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVO income statement (TTM) | |
|---|---|
| Revenue | UK£58.67m |
| Cost of Revenue | UK£45.63m |
| Gross Profit | UK£13.04m |
| Other Expenses | -UK£3.08m |
| Earnings | UK£16.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 10, 2024
| Earnings per share (EPS) | 0.024 |
| Gross Margin | 22.22% |
| Net Profit Margin | 27.47% |
| Debt/Equity Ratio | 0% |
How did HVO perform over the long term?
See historical performance and comparison